Chinese biotech company declares win in antibody dispute
I-Mab and Tracon collaborated to develop cancer treatments (Credit: Shutterstock/nednapa)
A China-based biotech company says it has defeated a damages claim worth more than US$200 million in an ICC case over a collaboration to develop cancer-fighting antibodies.
To read more
Subscribe to Global Arbitration Review
Register for limited access
Register for free to receive GAR’s daily briefing and access to GAR 100.
Register now
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Arbitration Review experts.
Subscribe now